News
Fount raises US$12m ahead of launching new women’s health products
The company is expected to launch its new products later this year
The human performance company Fount has secured US$12m in funding as it prepares to launch new sleep and women’s health products.
Fount began its work with professional athletes and Navy SEALs and now offers customised health and performance optimisation programmes through its flagship offering, Fount Pro.
According to developers, the programmes combine n=1 experimentation with one-on-one coaching and enable clients to optimise their energy, focus, mood, sleep, gut health, longevity, fertility, and body composition.
The company uses data sets and AI expertise to create new products, such as FlyKitt, a system meant to prevent jet lag by reducing inflammation and shifting your circadian rhythms.
“At Fount, we’ve taken our expertise in optimising outcomes for the highest performers in the toughest environments on Earth and built tools that can help anyone achieve their health and performance goals,” said Andrew Herr, founder and CEO of Fount.
“With this funding, we are expanding our world-class Fount Pro service and preparing to launch new products to solve high-impact challenges.
“The effectiveness of our products and services shows the value of merging the data from our experiment-driven approach with the latest AI technology.
“We will continue to leverage these advantages to make world-class tools available beyond pro sports and special operations.”
The funding round, led by Amity Ventures with participation from Los Angeles Dodgers-associated Elysian Park Ventures, Not Boring Capital, Allen & Co and Champion Hill Ventures, will help Fount launch a series of new products for sleep and women’s health, with results showing effects such as a 90 per cent reduction in symptoms of premenstrual syndrome.
CJ Reim, managing partner of Amity Ventures, said: “Many companies, protocols, or products offer point solutions delivering the latest diet, sensor, meditation practice, or fitness routine.
“Fount sits on top of all of these point solutions delivering a personalised, experiment-driven approach to implementing the health and performance interventions that work for you.
“We invested in Fount because they are the only company to bring together the health insights, data and AI expertise required to scale this to millions of people.”
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Wellness4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur6 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
News4 weeks agoVerdane invest in Clue to accelerate the future of women’s health






